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Abstract: The present work describes the synthesis of novel injectable, self-setting bone cements
made of strontium-substituted hydroxyapatite (Sr-HA), obtained by single-phase calcium phosphate
precursors doped with different amounts of strontium and enriched with alginate. The addition of
alginate improved the injectability, cohesion, and compression strength of the cements, without
affecting the hardening process. A Sr-HA cement exhibiting adequate hardening times and
mechanical strength for clinical applications was further tested in vivo in a rabbit model, in
comparison with a commercial calcium phosphate cement, revealing the maintenance of biomimetic
composition and porous microstructure even after one month in vivo, as well as enhanced ability to
induce new bone formation and penetration.
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1. Introduction
The development of injectable and self-hardening biomaterials able to regenerate damaged bones
by minimal invasive surgery is a topic of increasing interest, particularly for the treatment of vertebral
fractures [1–5], but also tibial plateau, proximal humerus, wrist and calcaneus [6], as well as hip and
femoral neck [7].
In this respect, complete bone regeneration still remains an unsolved clinical need, mainly due to
the unavailability of bone cements endowed with adequate bioactivity, porosity, and osteoconductivity
able to promote effective new bone formation and extensive cell proliferation upon hardening. Indeed,
it has been reported that the main drawback exhibited by commercially available bone cements is the
inability to be completely colonized by the new bone, thus affecting the establishment of well-integrated
bone-biomaterial constructs [8–10]. The impairment of the mechanical performance may be due to
both the excessive stiffness of the cement, as reported in the case of acrylic formulations [11–14], and
the low porosity, as reported in the case of calcium phosphate bone cements (CPCs) [1,15].
The hardening of acrylic bone cements (e.g., poly(methylmethacrylate), PMMA) is also reported
to occur through an exothermic polymerization, leading to the necrosis of the surrounding tissues [16].
In this respect, CPCs are considered as elective candidates for bone regeneration due to their
excellent biocompatibility, chemical similarity with bone tissue, and ability to harden in vivo at
body temperature.
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Several approaches have been proposed to prepare CPCs; among them, the one based on the
hydrolysis and transformation of α-Ca3(PO4)2 (αTCP) into elongated calcium-deficient hydroxyapatite
(HA) particles is particularly interesting and promising [1]. Indeed, the chemical reactions involved
in the cement hardening are isothermal and not subjected to pH variations, thus avoiding potential
cell injury. Calcium-deficient HA is also characterized by increased bioactivity and bio-resorbability,
if compared with stoichiometric HA [17]. Moreover, such cements can be endowed with enhanced
bioactivity by introduction of bio-competent ions (e.g., Mg2+, CO32−, SiO44−, and Sr2+) in the HA
lattice as substitutes of calcium or phosphate [18–21]. Strontium has been largely studied due to its
proven ability to restore the bone turnover balance, especially when the treatment of bone fractures
caused by osteoporosis is demanded [22,23]. As systemic pharmacological approaches based on
Sr-containing drugs often resulted in deleterious effects on bone mineralization due to reduction in
calcium absorption and possible alterations of the properties of the mineral bone [24], a controlled
delivery of relevant active principles in situ is highly desirable to provide safe and efficient therapies
against degenerative bone diseases. Some positive results on the efficacy of local release of strontium
were obtained in recent studies based on titanium implants functionalized with strontium [25] or
coated with Sr-substituted HA [26]. In addition, Sr-containing CPCs based on commercial αTCP and
soluble salts containing strontium (e.g., SrCO3, SrHPO4) were previously developed [27–29] and tested
in ovariectomized rats [30].
A major challenge for material scientists is the control of the chemistry and rheological properties
of injectable CPCs; indeed, process parameters, such as phase composition of the inorganic precursor,
particle size, liquid-on-powder ratio (L/P), polymeric additives are critical factors affecting their
viscosity, cohesion, and setting times [15]. In this respect, previous research reported improved cement
injectability and cohesion by decreasing the particle size of the starting powders, as well as using more
viscous solutions. However, in such conditions the increase of the cement cohesion was also associated
to an impairment of setting times and mechanical performance [31]. It was also reported that smaller
precursor particles favor the transformation into apatite, as well as the establishment of a more packed
structure and higher mechanical strength [32–34]. On the other hand, the introduction of foreign
ions into the calcium phosphate structure prolonged the setting times [29,35]. Among the various
approaches proposed to improve the hydraulic reactivity of the precursor powders, the high-energy
planetary ball milling was reported to be particularly promising in terms of optimal particle size
reduction efficiency [36]. Previous research was also dedicated to improve the rheological properties
of the cement by addition of organic compounds such as biopolymers [15]. In this respect, alginate
was reported as a biomaterial for bone tissue engineering, due to its biocompatibility, non-toxicity, and
biodegradability, as well as for its strengthening ability [37].
In the present work Sr-doped HA cements were prepared by mixing Sr-substituted αTCP phases,
appositely designed and synthesized to be the unique inorganic precursors, with disodium phosphate
solutions enriched with alginate. The process parameters, e.g., the powder milling and liquid-to-solid
ratio, were optimized to obtain adequate setting times and mechanical properties. The in vivo
performance of a selected cement formulation was preliminary evaluated at four weeks after surgery
into rabbit femur, in comparison with a commercial CPC, by compositional, morphological, and
histological/histomorphometric analysis.
2. Results
2.1. Physicochemical Properties and Setting Behavior
The ICP analysis of the Sr-αTCP phases detected the presence of strontium in amounts very close
to the nominal composition of the starting mixture (see Table 1).
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Table 1. ICP analysis of the as-obtained Sr-αTCP precursors and final cements.
Nominal Sr Concentration Actual Composition
Sr/(Ca + Sr) (mol %) Ca/P (mol) (Sr + Ca)/P (mol) Sr/(Ca + Sr) (mol %)
0 1.51 1.51 0
2 1.44 1.46 1.8
5 1.40 1.46 4.9
The XRD patterns of the as-obtained powders show peaks that can be ascribed to αTCP (ICDD:
29-0359) and βTCP phases (ICDD: 09-0169). No XRD reflections belonging to other crystalline phases
were detected (see Figure 1a). Semi-quantitative evaluation of the phase composition reported the
formation of βTCP phase (in the range 7–12 wt %) in the as-prepared materials, slightly increasing
with the strontium content.
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Figure 1. XRD diffraction profiles of: (a) cement precursors with different Sr content (Sr/Ca: 0–5 mol %);
(b) the corresponding hardened cements after 3 days of incubation at 37 ◦C. The • symbol indicates the
peaks belonging to βTCP phase. In Figure 1a the non-indexed peaks address αTCP phase, whereas in
Figure 1b, the HA phase.
The phase composition of the cements obtained after thre day of incubation at 37 ◦C in
a thermostated water bath was also inv stigated, showing the complete transformation of αTCP
into HA phases, while preserving small amounts of βTCP (see Figure 1b).
A steady shift of the peaks towards higher d values and a quasi-linear increase of the lattice
parameters were observed in both α and βTCP phases. A similar effect was also detected for the HA
phases of the corresponding hardened cements (Table 2).
Table 2. Linear dependence of lattice parameters and volume vs. Strontium content: y = y0 + m·xSr.
y0 refers to Sr-free composition, xsr: strontium content (%),m: extent of variation with the strontium content.
αTCP y0 m R2
a 12,849 Å 0.0074 0.988
b 27,340 Å 0.0151 0.988
c 15,217 Å 0.0029 0.987
Beta angle 126.30◦ 0.01616 0.963
Cell volume 4308 Å3 5.46 0.989
Cell volume [38] 4318 Å3 4.86 –
βTCP y0 m R2
a 10,414 Å 0.0047 0.93
c 37,341 Å 0.01281 0.993
Cell volume 3501 Å3 4.45 0.967
Cell volume [39] 3507 Å3 4.90 –
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Table 2. Cont.
HA y0 m R2
a 9.45717 Å 0.00274 0.997
c 6.87681 Å 0.00324 0.998
Cell volume 532.8 Å3 0.56 0.998
Cell volume [40] 528.0 Å3 0.85 –
Cell volume [41] 527.0 Å3 0.71 –
The Sr-free αTCP phase (Sr0) exhibited a domain size D = 362 ± 8 nm and a steady increase of
the coherent domain was observed by increasing the strontium content, according to the quasi-linear
trend D = 299.6 + 11.4x (R2 = 0.98), where x is the Sr/(Ca + Sr) percentage molar ratio. The domain size
of βTCP showed much lower values, in the range 100–150 nm.
The average domain size of Sr-HA was about 25 nm, nearly irrespective of the strontium amount.
The full width half maximum of (300) and (002) reflections (d ∼= 2.72 and 3.44 Å, respectively) were
also separately evaluated, thus achieving the size of coherent domains along both the ab plane and
the c axis: it was found that the introduction of strontium progressively induced anisotropic crystal
growth along the c axis (Figure 2a), leading to the distortion of the HA lattice (Figure 2b) according
to the quasi-linear trend c/a = 0.73 + 1.8 × 10−4x (R2 = 0.99), where x is the Sr/(Ca + Sr) percentage
molar ratio.
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The cement formulations enriched with alginate exhibited improved injectability and cohe ion of
the paste, without demixing or cement fragmentation after 30 min of immersion into Hanks’ balanced
salt solution at 37 ◦C (Figure 3).
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The presence of alginate did not negatively affect the setting reactions, while a weak retarding
effect on the phase transformation was observed, especially for Sr5. On the other hand, the introduction
of strontium retarded both the setting times and the transformation of Sr-αTCP into Sr-HA (Table 3
and Figure 4).
Table 3. Setting times of Sr-substituted formulations.
Setting Solution Cement Tin (min) Tfin (min)
without Alginate
Sr0 10 ± 1 22 ± 3
Sr2 13 ± 1 30 ± 3
Sr5 23 ± 3 47 ± 3
with Alginate
Sr0 9 ± 2 17 ± 2
Sr2 11 ± 2 26 ± 3
Sr5 25 ± 3 51 ± 2
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2.2. Morphological and Mechanical Aspects
The Sr-doped cements exhibited nano-sized elongated crystals developed upon heterogeneous
nucleation and growth on the surface of the precursor particles (Figure 5), thus enabling the
establishment of an extensive micron-sized porosity, irrespective of the extent of strontium doping.
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The overall porosity of Sr0, Sr2 and Sr5 cements was calculated as 51% ± 2%, 46% ± 3%, and
49% ± 1%, respectively.
The presence of alginate significantly improved the compressive strength and Young’s modulus of
the cements at three days after immersion into Hanks’ balanced salt solution at 37 ◦C, when compared
with alginate-free formulations (Figure 6).
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Figure 6. Effect of alginate on the co i trength (a) and Young’s mod lus (b) of Sr-doped
cements after three days of immersion. * p . ; ** 0.1; *** p < .01.
The Sr2 cement exhibited the highest compressive strength. The long-term compressive strength
of Sr2 was also tested, exhibiting σ = 28.1 ± 1.2 MPa and Young’s modulus E = 2.3 ± 0.2 GPa after
30 days of immersion in physiological conditions.
On the basis of these results, the compressive strength of Sr2 cement was also tested in comparison
with KyphOs cement, which was the control of the in vivo tests. At one, and after three, days of
incubation, the KyphOs cement exhibited higher compressive strength than Sr2, and also significantly
lower porosity (Figure 7).
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2.3. Biological Evaluation by in Vitro Cell Tests
The incorporation of both strontium and alginate did not induce cytotoxicity, leading to a higher
percentage of viable cells. The intracellular esterase activity and plasma membrane integrity were
preserved. Only a few dead cells (stained in red) were observed (Figure 8a–c). Analysis of cell
morphology carried out with SEM showed nearly complete coverage of Sr2 cement by well-spread
cells (Figure 8d) and cell plasma extensions were evident (Figure 8e).
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morphology assessed by SEM: (d) MG63 grown for three days on Sr2 surface (scale bar: 50 µm) with
a higher power view showing details of the cell plasma extensions (e) (scale bar: 20 µm).
2.4. In Vivo Pilot Experiment and Histological Analysis
A pilot in vivo test was carried out to investigate the performance of Sr2 cement, selected for
composition, setting, and the mechanical properties in accordance with the clinical need, in comparison
with KyphOs FS™, Medtronic Spine LLC, Minneapolis, MN, USA, a polymer-free commercial CPC [8].
The histological analysis of the explants at four weeks after the injection in vivo evidenced an intimate
contact between the bone cements and the surrounding bone, without inflammatory processes,
fractures or infections (Figure 9).
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The histomorphometric parameters bone-material contact rate (BMCR) and bone penetration
rate length (BPR-Le) (see Table 4) were used to quantify bone-material interaction and new bone
penetration, thus showing significantly enhanced formation of new bone around Sr2 cement, when
compared with the control cement (Figure 10).
Table 4. Parameters observed and evaluated in histomorphometric analysis.
Parameter Abbreviation Formula
Material Perimeter M-Pm –
Bone Material Contact Length BMC-Le –
Bone Pores Length BPo-Le –
Material Diameter M-Dm –
Bone Material Contact Rate BMCR (BMC-Le/M-Pm) × 100
Bone Penetration Rate Length BPR-Le (BPo-Le/(M-Dm/2)) × 100
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Explanted tissues treated with Sr2 and control cement were subjected to XRD analysis to
investigate the phase composition. Complete transformation of α-TCP into HA was detected in
the sample treated with Sr2, so that only low-crystallinity HA and unreacted βTCP were detected.
Additionally, the profile f he HA pattern exhibited a significant peak broadening, if compared with
the HA phase btained after immersion of Sr2 for three days in Hanks’ balanced salt solution at
37 ◦C, thus suggesting a decr ase in the crystal order possibly due to the long term permanence of the
cement in vivo (Figu e 11). In particular, the domain size along (300) direction (i.e., the ab plane) was
reduced fr m 19.9 ± 0.7 to 9.6 ± 1.8 nm, whereas along the (002) direction (i.e., the c axis) it decreased
from 62.9 ± 1.6 to 34.3 ± 2.2 nm. The explanted tissue treated with KyphOs showed the presence
of a low-crystallinity HA phase, but was associated with a significant amount of residual precursor
phases, including αTCP, thus ndicating that the transformati n process was not complete after on
month in vivo.
Furthermore, SEM analysis of he e plants highlighted mar ed difference in the cement
microstructure af er setting in vitro and in vivo, as Sr2 still exhibited after implantation a diffuse
microporo ity after one month in vivo, contrary to the control (Figure 12).
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3. Discussion
In the present work, Sr-substituted αTCP phases were synthesized as a unique inorganic precursor
for the developm nt of apatitic b ne cements. For the first time, Sr-substituted apatit c ce ents were
obtained by inc rporati sodium algin te nd tested both in vitro and in a small in vivo pilot study.
The cements were optimized to fulfill specific requirements for clinical applications in terms of
hardening times and mechanical strength [42,43].
The precursor synthesis, based on solid state reactions followed by fast quenching, generated
Sr-doped αTCP phases with limited amounts of βTCP polymorph, slightly increasing with the
strontium content, as previously reported [3]. This results are in compliance with the larger ionic
radius of strontium compared with calcium (Sr2+ ionic radius = 0.113 nm; Ca2+ ionic radius = 0.099 nm)
and in good quantitative agreement with the data provided in previous works [38–41]. In this respect,
the detection of Sr amounts very close to the nominal composition of the starting mixture (Table 1),
associated with the absence of secondary phases other than TCP (Figure 1) and the simultaneous
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increase of the lattice parameters (Figure 2), confirmed the incorporation of strontium into the TCP
crystal lattices and in the final HA phase obtained upon cement setting.
The achievement of complete injectability, associated with adequate setting times, is reported to
be one of the most critical issues of CPCs [8]; in this respect, the addition of polymeric additives into
CPCs has been widely investigated in previous research to enhance the rheological properties, but the
precise control of their effect still remains challenging [44].
In our cements, characterized by ionic substitutions with strontium and the presence of alginate,
a significant retard in both setting times (Table 3), and the transformation of TCP phases into apatite
(Figure 4) were detected. However, this effect can be mainly ascribed to the presence of strontium, as
also hypothesized in previous works [3,20,45], whereas the effect of alginate appeared as negligible.
As a general rule, comparative analyses among the various cements reported in literature are
made quite difficult by the variety of different, and often incomparable, preparation routes [20], thus
often leading to contradicting results.
It was reported that the incorporation of biopolymers can improve the functional properties of
CPCs [44]. In this respect, despite previous research reporting the addition of alginate as deleterious
for the mechanical performance of αTCP-based CPCs formulations [46], in the present work the use of
alginate significantly improved both injectability and cohesion (Figure 3), leading also to significantly
higher mechanical strength when compared with alginate-free cements (Figure 6). The effect of
strontium on the mechanical strength appeared as negligible in alginate-free cements up to Sr2, while
Sr5 exhibited the lowest values; a similar trend, but with greater statistical difference, was also detected
among the alginate-containing cements, with Sr2 exhibiting the highest compressive strength (Figure 7),
even comparable to previously-reported CPCs reinforced with fibers [15].
The reinforcement mechanism provided by alginate could be due to a crack bridging effect,
similarly to what proposed by [47] in the case of cellulose-containing CPCs.
On the other hand, a previous study reported a decrease of the mechanical strength of Sr-CPCs
above a certain threshold of strontium [48], possibly due to the higher occurrence of crystal lattice
distortion related to strontium’s larger ionic radius; in our study, we observed a similar effect for
Sr/(Sr + Ca) above 2 mol %.
For the first time the biological effect of strontium doping and alginate into an apatitic cement was
tested with MG63 cells, resulting in excellent proliferation and spreading of the seeded cells (Figure 8).
This finding confirms previous studies reporting beneficial effects of strontium on cell proliferation
in vitro [20], while the absence of cytotoxic effects related to alginate was assessed, supporting its use
in the development of biomaterials for bone regeneration.
On the basis of adequate cement composition and setting time for clinical applications [42,43],
the Sr2 cement was selected to be mechanically and in vivo tested in comparison with KyphOs,
a commercial strontium-containing apatitic cement [8] as control. After one month in vivo the Sr2
cement showed significantly higher bone-material contact and bone penetration (Figures 9 and 10),
perhaps due to the higher porosity. It might be also hypothesized that the presence of alginate
favored the penetration of bone tissue into the cement by progressive bio-erosion in vivo. Comparative
in vivo tests should be performed to support this hypothesis; however, in the present work we found
that alginate-free pastes did not reach acceptable rheological and mechanical properties, as well as
adequate setting times when injected in liquid media, so as to be considered as not interesting for
real applications.
The XRD analysis of the explanted tissues reported that the composition of the control cement did
not change significantly after one month in vivo, with only a partial conversion of the precursors into
hydroxyapatite. Conversely, Sr2 exhibited complete transformation into hydroxyapatite in vivo, thus
leading to the establishment of a completely biomimetic composition (Figure 11). In Sr2, the analysis
of the HA peak profile evidenced a marked reduction of the crystal domain size. In this respect, it can
be hypothesized that Sr2 underwent also a degradation process following the new bone formation
and penetration.
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The SEM analysis of the explants reported the maintenance of an extensive microporosity in Sr2
even after one month in vivo, while a more packed structure was exhibited by the control cement, that
might have limited bone penetration into the cement mass (Figure 12). KyphOs exhibited significantly
higher compressive strength but also lower overall porosity (Figure 7). Porosity substantially influences
both the biological activity and the mechanical properties of biomaterials, therefore their optimization
is a key aspect in the development of a bone cement. The microporosity of CPCs, which usually varies
between 30% and 55%, is significantly dependent on the L/P ratio: the higher the L/P ratio, the higher
the microporosity [15]. Therefore, to optimize these two properties, L/P ratio was maintained at the
lowest value enabling complete injection and adequate cohesion. The final L/P of Sr2 resulted slightly
higher than the control cement, i.e., 0.48 and 0.43, respectively; this yielded a much higher porosity
associated with nanosized elongated crystals, as typically occurs in apatitic CPCs [3,49,50], which
might have favored osteointegration.
The bioactivity and effective osteointegration of a bone scaffold are key aspects to trigger and
sustain bone regeneration in critical size defects [51]. In this respect, the approach presented in
this work enabled the preparation of Sr-substituted HA cements with controlled and biomimetic
composition, with defined strontium content replacing calcium in the lattice of HA, associated to
excellent injectability, cohesion, and stable compressive strength enabling mechanical loading. The new
cement maintained also high bioactivity and porosity in vivo, making these new pastes interesting for
future applicative purposes.
Although other cement formulations (e.g., PMMA-based cements) enable the early-stage
mobilization of the patient after surgery due to high mechanical strength, their intrinsic bioinertness
prevent effective bone regeneration. In this respect, the implantation of bioactive apatitic pastes able to
completely transform into apatite while maintaining a microporous structure can be elective for bone
regeneration, due to the extensive colonization by new bone that can also improve the mechanical
performance of the implant over time, as already evidenced in previous studies [52,53]. This is
particularly relevant in the case of young and still physically active patients, for whom effective bone
regeneration is of paramount importance to restore the physiological bone functionality.
4. Experimental Section
4.1. Preparation of the Inorganic Precursors
Sr-substituted αTCP powders with different strontium content (i.e., Sr/(Ca + Sr) = 0, 2, 5 mol %,
henceforth coded as Sr0, Sr2, Sr5, respectively) were synthesized by solid state reaction of stoichiometric
amounts of calcium carbonate (CaCO3, Sigma Aldrich, St. Louis, MO, USA), dicalcium phosphate
dibasic anhydrous (CaHPO4, Sigma Aldrich) and strontium carbonate (SrCO3, Sigma Aldrich),
following the reaction:
xSrCO3 + (1− x)CaCO3 + 2CaHPO4 → Ca3−xSrx(PO4)2 + H2O+ CO2
The powders were dry mixed for 30 min, then pressed to form pellets and finally treated at 1400 ◦C
for 1 h in a platinum crucible. The pellets were removed from the hot furnace and rapidly crushed into
small pieces to stabilize the αTCP phase against the re-crystallization of βTCP [5]. Then, the as-obtained
product was sieved below 150 µm and milled by planetary mono mill (Pulverisette 6 classic line,
Fritsch, Germany). In detail, the powder was dispersed in pure ethanol and milled for 50 min at
400 rpm using a zirconia jar with 5 mm diameter grinding media (ball-to-powder weight ratio = 2).
Aqueous solutions of disodium hydrogen phosphate dehydrate, 5 wt % (Na2HPO4·2H2O,
Fluka), and sodium alginate, 2 wt % (Alginic Acid Sodium Salt from Brown Algae, Sigma Aldrich)
were prepared.
The solid and liquid components were sterilized with γ irradiation (25 kGy) and autoclave (121 ◦C
for 20 min), respectively, and mixed with the powders according to a liquid-to-powder (L/P) ratio
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equal to 0.48. The mixing procedure of the cement components and the extrusion of the cement were
performed by commercial equipment (P-system, Medmix, Rotkreuz, Switzerland).
Polymer-free formulations were obtained without adding sodium alginate into the solution.
The control cement (KyphOs FS™, Medtronic Spine LLC, Minneapolis, MN, USA), was prepared
by mixing the powder and the liquid [8] with liquid-on-powder ratio equal to 0.43, according to the
procedure included in the commercial package.
4.2. Characterization of the Pastes and Hardened Cements
4.2.1. Composition and Crystallographics
The elemental composition was evaluated by inductively-coupled plasma optical emission
spectroscopy (5100 ICP-OES, Agilent Technologies, Santa Clara, CA, USA). The cement precursors were
analyzed by dissolution of 20 mg of powders into 2 mL of nitric acid (HNO3, Sigma Aldrich), followed
by dilution to 100 mL with bi-distilled water; three specimens were tested for each cement formulation.
The XRD patterns were acquired in the 2θ range 10◦–80◦, with a scan step of 0.02◦, counting 0.5 s
(D8 Advance, Bruker AXS equipped with a LINXEYE detector, Karlsruhe, Germany). Upon subtraction
of the instrumental broadening, the collected XRD patterns were evaluated by Rietveld method (TOPAS
5 software, Bruker AXS, Karlsruhe, Germany) to simultaneously refine the scale factor, peak position,
and peak broadening, thus obtaining the content of crystalline phases present, the lattice parameters
and domain sizes. The Rietveld analysis was carried out by using the crystal models of Sr-free
αTCP [54], βTCP [55] and HA [56] phases. The hardened cements were analyzed after three days of
soaking in Hanks’ balanced salt solution (H6648, Sigma Aldrich) at 37 ◦C.
4.2.2. Injectability and Setting Times
The cement injectability was qualitatively evaluated by measuring the amount of cement in the
syringe after extrusion [33]. The initial and final setting times of the cements (indicated as Tin and
Tfin, respectively) were evaluated by Gillmore apparatus, according to ASTM C266-99, testing five
specimens for each composition, upon immersion in Hanks’ balanced salt solution at 37 ◦C. On the
basis of setting times appropriate for the clinical practice, we considered an initial setting time≤15 min
as a threshold.
4.2.3. Morphological Characterization
The morphology of the cements was observed by scanning electron microscopy (SEM: FEI,
Quanta 200, Hillsboro, OR, USA) after immersion in Hanks’ balanced salt solution at 37 ◦C for 3 days.
The porosity percentage was evaluated on hardened cylindrical specimens, as P = 1 − ρ/ρ0, where
ρ is the cement density calculated as weight-on-volume ratio and ρ0 is the theoretical density of the
hydroxyapatite phase (3.16 g/cm3).
4.2.4. Mechanical Evaluation
The compressive strength and Young’s modulus of cements were evaluated by testing cylindrical
specimens (n. 12 samples; diameter = 8 mm; height = 17 mm) obtained after hardening in teflon moulds
for 30 min and then immersed in Hanks’ balanced salt solution at 37 ◦C for three days. The tests
were performed in displacement control at 1 mm/min by a universal testing machine (MTS Insight 5,
Eden Prairie, MN, USA). The planarity of the endplates was obtained by using an automatic surface
grinder (VAM Rettificatrici, Cuggiono, Italy).
Long term evaluation of a selected cement was carried out in agreement with ISO 9917 by testing
cylindrical specimens (diameter = 8 mm; height = 17 mm) up to 30 days of soaking in Hanks’ balanced
salt solution [57] at 37 ◦C (n. 12 samples were tested).
The Young’s modulus was approximated by calculating the slope of the linear, elastic portion of
the stress–strain curves until the failure stress of the specimen. The statistical analysis of data was
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made by a two-way analysis of variance (ANOVA) followed by Sidak’s multiple comparisons test
(GraphPad 6.0, GraphPad Software, La Jolla, CA, USA).
4.2.5. Cell Culture
The cytocompatibility of alginate-containing cements was investigated by direct cell culture with
human osteoblast-like cell line (MG63 cell line) purchased from Lonza (Basel, Switzerland). The cells
were cultured in Dulbecco Modified Eagle’s (DMEM)/F12 Medium (Gibco, Waltham, MA, USA),
containing penicillin-streptomycin (100 U/mL–100 µg/mL) supplemented with 10% fetal bovine
serum (FBS) and kept at 37 ◦C in an atmosphere of 5% CO2. For the experiments, cells were plated at
1.5 × 104/cm2 and cultured for up to three days. Cylindrical cement specimens (diameter = 10 mm
and height = 2 mm) were sterilized with three washes in ethanol 70% for 20 min followed by three
washes in 1X PBS for 10 min each. Samples were then air dried and sterilized by UV irradiation for
30 min per side under a laminar flow hood and preconditioned for three days in cell culture medium
supplemented with FBS and penicillin-streptomycin.
Then, samples were placed one per well in a 24 well plate and a drop of 50 µL containing the cell
suspension was seeded on the center of the upper discs surface allowing the cell attachment for 30 min
in the incubator, before adding 1.5 mL of cell culture medium into each well.
All cell-handling procedures were performed in a sterile laminar flow hood. All cell culture
incubation steps were performed at 37 ◦C with 5% CO2 and controlled humidity.
4.2.6. Cell Viability Assay
A live/dead assay kit (Invitrogen, Carlsbad, CA, USA) was performed according to the
manufacturer’s instructions. Briefly, the samples were washed with 1X PBS for 5 min and incubated
with calceinacetoxymethyl (Calcein AM) 2 µM plus ethidium homodimer-1 (EthD-1) 4 µM for 15 min
at 37 ◦C in the dark, the samples were rinsed in 1X PBS [58]. Images were acquired by an inverted
Nikon Ti-E fluorescence microscope (Nikon, Tokyo, Japan). One sample per cement was analyzed at
day three.
4.2.7. Cell Morphology Evaluation
The samples were washed with 0.1 M sodium cacodylate buffer pH 7.4 and fixed in 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer pH 7.4 for 2 h at 4 ◦C, washed in 0.1 M sodium
cacodylate buffer pH 7.4 and dehydrated in a graded series of ethanol for 10 min each. After sputter-coating
with gold, the samples were observed by scanning electron microscopy.
4.2.8. In Vivo Pilot Experiment and Histological Analysis
The in vivo performance of a selected Sr-doped cement was assessed by implantation in three New
Zealand White (NZW) male rabbits (weighing about 3 kg) for each cement. The tests were conducted
with previous approval of the institutional Ethical Committee strictly following Italian (Law by Decree,
27 January 1992, No. 116), European (Directive 86/609/EEC) and International Laws and Regulations
(ISO 10993-2-Animal Welfare Requirements). The cements were implanted according to a previously
reported procedure [18,59,60]. Briefly, a blind tunnel (diameter = 4 mm; length = 8 mm) was aseptically
created under fluoroscopic control by a surgical drill in the meta-epiphyseal distal zone of both femurs,
then irrigated with a saline solution and filled by injection with the cements. All the procedures
were performed under general anesthesia (ketamine 10 mg/kg + xylazine 0.3 mg/kg Intramuscular,
isoflurane + oxygen + nitrogen protoxide with mask) with daily veterinary control. At four weeks
after surgery, the animals were pharmacologically euthanized with intravenous administration of
Tanax. The femurs were then harvested and the surrounding soft-tissue was removed. The presence of
deformities or fractures and the bone-cement interface were investigated. For histological analysis,
the harvested specimens were fixed in phosphate-buffered 4% paraformaldehyde and stored at
4 ◦C for 12 h until processing. Then, the specimens were embedded in Technovit 7200, according
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to the manufacturer’s protocol (Exakt, Norderstedt, Germany). By using a saw microtome (Leica
Microsystems Srl, Milano, Italy), three consecutive central sections (30 ± 10 µm) were cut and stained
with toluidine blue. The region of interest (ROI) was made by tracing over the material followed by
a 100 pixel increase to include the bone-cement interface.
The microscopic examination was performed by an optical microscope (Carl Zeiss Axioscop
40 equipped with Axiocam ICC 3 Zeiss, Oberkochen, Germany) and Axiovision 4.8 software (Zeiss,
Oberkochen, Germany). Standard terms and nomenclature for bone histomorphometric analysis were
used, according to [61]. The statistical analysis of data, expressed as mean ± SEM (standard error of
the mean), was made by an unpaired t-test (GraphPad software 6.0).
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